Philips Receives FDA Clearance for Its New Oximetry Sensor
Philips has obtained FDA 510(k) clearance for its new generation reusable sensor that measures oxygen saturation. This regulatory approval strengthens the group's range of monitoring solutions in the field of pulse oximetry.
The approved sensor represents a technological advancement in the reliable measurement of oxygen saturation. According to the group, this new model is based on rigorous validation and is aimed at diverse patient populations. Philips claims that this solution enhances its ability to provide reliable measurements that support clinical management.
The Group's Commitment to Monitoring
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
This approval highlights Philips' strategic direction towards strengthening its portfolio of health solutions. The group asserts its commitment to providing clinicians with trustworthy tools that ensure the safe management of each patient.
SectorSanté · Technologie · Dispositifs médicaux›Équipements Médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 3.9MD€
Free cash flow: 28M€
Guidance from the release
Nous avons délivré un bon départ en 2026.
Bonne performance au T1, croissance des ventes et des marges.
Risks mentioned
Impact des tarifs et inflation des coûts sur les marges.
Environnement macroéconomique incertain impactant les performances.
Opportunities identified
Croissance des ventes comparables de 4% dans tous les segments.
Augmentation du carnet de commandes grâce à des innovations.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
